Loading clinical trials...

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension | Clinical Trials | Clareo Health

TERMINATEDPHASE2

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Proof-of-concept Study to Evaluate the Efficacy and Safety of LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

NCT01373086•Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

This study will assess the efficacy and safety of LFF269 compared to placebo after treatment in subjects with essential hypertension.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Male and female (post-menopausal or surgically sterile).
•2. Age from 18 to 75 years inclusive.
•3. Subjects with mild-to-moderate uncomplicated essential hypertension, with (not more than 2 in combination) or without prior treatment.
•4. Subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 - 36 kg/m2.

Exclusion Criteria

•1. History or evidence of a secondary form of hypertension,
•2. History of cardiovascular disease. Type 1 or type 2 diabetes mellitus.
•3. Clinically significant valvular heart disease.

Locations (11)

Advanced Clinical Research Institute-Phase I

Anaheim, California, United States

Comprehensive Phase I

Fort Myers, Florida, United States

Comprehensive Phase One®,

Miramar, Florida, United States

Comprehensive NeuroScience

St. Petersburg, Florida, United States

Clinical Research Atlanta

Stockbridge, Georgia, United States

Clinical Research Advantage/ Prairie Fields Family Medicine, PC

Fremont, Nebraska, United States

Internal Medicine Physicians

Omaha, Nebraska, United States

ICON Developmental Solutions

Omaha, Nebraska, United States

Clinical Research Advantage/ Aloha Medical

Las Vegas, Nevada, United States

ICON Development Solutions,

San Antonio, Texas, United States

Key Dates

Start Date

May 1, 2011

Primary Completion Date

October 1, 2011

Completion Date

October 1, 2011

Last Updated

December 17, 2020

Enrollment

ACTUAL participants

Conditions

Hypertension

Interventions

LFF269

DRUG

Eplerenone

DRUG

Placebo

DRUG

Natural History of Noncirrhotic Portal Hypertension

NCT02417740

Cystic FibrosisImmunologic Deficiency Syndrome+3 more

View study

RECRUITING

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

NCT07480265

Hypertension (HTN)Hyperhomocysteinemia+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 17, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

Inclusion Criteria

Exclusion Criteria

Natural History of Noncirrhotic Portal Hypertension

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication

Penn Medicine Healthy Heart

Preliminary Human Trials of F230 Tablets